Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI)

Sponsor
Clalit Health Services (Other)
Overall Status
Completed
CT.gov ID
NCT04709003
Collaborator
(none)
1,567
6
6.2
261.2
42.1

Study Details

Study Description

Brief Summary

Although clinical trials for approved COVID-19 vaccines demonstrated efficacy of the vaccine in preventing symptomatic infection, many questions about vaccine effectiveness, such as the effectiveness of COVID-19 vaccine in preventing asymptomatic infection, a surrogate for transmission, and duration of protection, can only be evaluated in real-world trials. The objective of the study is to evaluate COVID-19 vaccine effectiveness (Pfizer vaccine, and, if available, Moderna vaccine) in preventing infection in healthcare personnel in Israel. HCP who are Clalit members and working in Soroka, Beilinson, Meir, Haemek, Kaplan and Schneider hospitals, 18 years or older, and eligible to get COVID-19 vaccine according to Ministry of Health guidelines, will be recruited, regardless of their intention to get the COVID-19 vaccine. A baseline serology sample and respiratory sample will be collected. Participants will be asked to provide a respiratory sample weekly for 3 months, and then monthly for the remainder of the study. Participants will also have blood drawn at 1 month, 3 months, 6 months, 9 months and 12 months. Respiratory samples will be tested for SARS-CoV-2 by RT-PCR; serology will be tested for SARS-CoV-2 antibodies. The study will last for 12 months. For each participant, data will be extracted from the Electronic Medical Record for the period of the study and retrospectively from 2010.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Serologic test
  • Diagnostic Test: Respiratory swabs

Study Design

Study Type:
Observational
Actual Enrollment :
1567 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI): A Prospective Cohort Study
Actual Study Start Date :
Dec 23, 2020
Actual Primary Completion Date :
Jun 30, 2021
Actual Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
vaccinated

participants who received the Covid-19 vaccine

Diagnostic Test: Serologic test
A blood test to check antibodies type and amount

Diagnostic Test: Respiratory swabs
PCR test to Covid-19

unvaccinated

participants who didn't received the Covid-19 vaccine

Diagnostic Test: Serologic test
A blood test to check antibodies type and amount

Diagnostic Test: Respiratory swabs
PCR test to Covid-19

Outcome Measures

Primary Outcome Measures

  1. COVID-19 vaccine effectiveness (VE) [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers

Secondary Outcome Measures

  1. Symptomatic SARS-CoV-2 infection in vaccinated vs. unvaccinated healthcare workers [18 months]

    Incidence of symptomatic SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers

  2. asymptomatic SARS-CoV-2 infection in vaccinated vs. unvaccinated healthcare workers [18 months]

    Incidence of symptomatic SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers

  3. Duration of effectiveness of the vaccine [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers over different periods of time

  4. Vaccine Effectiveness by age [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers of different age groups

  5. Vaccine Effectiveness by comorbidity [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers by various underly medical conditions

  6. Vaccine effectiveness in persons previously infected with SARS-CoV-2 virus [18 months]

    Incidence of SARS-CoV-2 infections in previously infection healthcare workers vaccinated with COVID-19 vaccine compared to previously infection unvaccinated healthcare workers

  7. VE by degree of exposure to COVID-19 patients [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers by degree of occupational exposure to COVID-019 patients

  8. VE by different SARS-CoV-2 variants [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with COVID-19 vaccine compared to unvaccinated healthcare workers for different variant strains of SARS-CoV-2

  9. Vaccine effectiveness of one dose compared to two doses [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with two doses of COVID-19 vaccine compared to healthcare workers vaccinated with two doses of COVID-19 vaccine

  10. Compartive vaccine Effectiveness of different vaccine brands [18 months]

    Incidence of SARS-CoV-2 infections in healthcare workers vaccinated with different brands of COVID-19 vaccine

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 120 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Any HCP at any of the participating hospitals who is

  • a member of Clalit Health Services

  • is eligible to get the Covid-19 vaccine

  • did not receive the first dose of COVID-19 vaccine more than 21 days prior to the enrollment date

Exclusion Criteria:
Employees at any of the participating hospitals will be excluded if they are:
  • not a member of Clalit Health Services; or

  • not eligible to get the Covid-19 vaccine according to the Ministry of Health guidelines; or

  • Less than 18 years of age

  • Received first dose of COVID-19 vaccine more than 21 days prior to date of enrollment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Haemek Medical Center Afula Israel
2 Soroka Medical Center Be'er Sheva Israel
3 Meir Medical Center Kefar Saba Israel
4 Beilinson hospital Petach Tikva Israel
5 Schneider Children's Medical Center of Israel Petah tikva Israel
6 Kaplan Medical Center Reẖovot Israel

Sponsors and Collaborators

  • Clalit Health Services

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ran Balicer, Chief Innovation Officer, Clalit Health Services, Clalit Health Services
ClinicalTrials.gov Identifier:
NCT04709003
Other Study ID Numbers:
  • 1051-20-RMC-C
First Posted:
Jan 14, 2021
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022